Overdiagnosis

Is blood pressure reading more accurate at home or clinic?

Retrieved on: 
Thursday, March 3, 2022
Diagnosis, Patient, Journal, Research, Health education, Health promotion, MPH, Kaiser Permanente, Method, Blood pressure, Internal medicine, Pharmacy, Overdiagnosis, Kidney, Journal of General Internal Medicine, American Heart Association, Stroke, Caregiver, Physician, Health, District, Hypertension, Health information management, ABPM, Randomized controlled trial, Pharmaceutical industry, Medical device, MD

"Blood pressure varies a lot over the day about 30 points systolic and 1 or 2 measurements in clinic may not reflect your average blood pressure," said Beverly B.

Key Points: 
  • "Blood pressure varies a lot over the day about 30 points systolic and 1 or 2 measurements in clinic may not reflect your average blood pressure," said Beverly B.
  • "Home blood pressure monitoring allows you to collect many more readings and average these."
  • In addition to these measures, every participant received 24-hour ambulatory blood pressure monitoring, or ABPM, the gold standard test for making a new diagnosis of hypertension.
  • While the guidelines recommend ABPM or home blood pressure monitoring before making a hypertension diagnosis, research shows that providers continue to use in-clinic measurement when conducting the second reading.

GRAIL Announces Validation of Its Multi-Cancer Early Detection Test Published in Annals of Oncology

Retrieved on: 
Tuesday, March 31, 2020
Research, Publishing, Genetics, Clinical trials, Communications, Biotechnology, Health, Science, Oncology, Other Science, RTT, Cancer screening, Medicine, Cancer, Clinical medicine, Prostate cancer, Oncology, Overdiagnosis, CCGA, GRAIL’s Multi-Cancer Early Detection Test, GRAIL

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced validation data for its multi-cancer early detection blood test were published in Annals of Oncology .

Key Points: 
  • GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced validation data for its multi-cancer early detection blood test were published in Annals of Oncology .
  • These findings support the potential significant public health benefit of an accurate and highly specific multi-cancer early detection test.
  • GRAILs multi-cancer early detection test is designed to detect cancers in early stages, when the chance of survival is higher than if cancer is detected after symptoms appear.
  • GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured.

PrediLife and the Institut Curie Announce a Partnership Covering Genetic Analyses for MammoRisk®, the Next-Generation Test Predicting the Risk of Breast Cancer

Retrieved on: 
Monday, May 6, 2019
Health, Biotechnology, Medical devices, Oncology, Pharmaceutical, Other Health, Research, Other Science, Science, RTT, Medicine, Clinical medicine, Health, Hereditary cancers, Cancer screening, Breast cancer, Mammography, Projectional radiography, Cancer, Overdiagnosis, Breast cancer screening

These include their restriction to the over 50s, the risk of over-diagnosis, the problem of cancers developing between two mammograms, and false positives.

Key Points: 
  • These include their restriction to the over 50s, the risk of over-diagnosis, the problem of cancers developing between two mammograms, and false positives.
  • Some of these polymorphisms have been associated with a higher risk of breast cancer.
  • The partnership between PrediLife and the Institut Curie will initially study around a hundred polymorphisms associated with a higher risk of breast cancer, with the Institut Curie performing the genetic analyses incorporated in the MammoRisk score.
  • This partnership is an endorsement of the reliability of our solution for predicting the risk of breast cancer.